Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial).
about
Efficacy and safety of nesiritide in patients with decompensated heart failure: a meta-analysis of randomised trialsNesiritide in acute decompensated heart failure: current status and future perspectivesA review of the renal and neurohormonal effects of B-type natriuretic peptide.Out-patient management of chronic heart failure.Cardiovascular and metabolic effects of natriuretic peptides.Administration of a large nesiritide bolus dose in a pediatric patient: case report and review of nesiritide use in pediatrics.Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide.Nesiritide: harmful or harmless?Controversy and conflict in the treatment of acute decompensated heart failure: nesiritide as evidence-based treatment.Controversy and conflict in the treatment of acute decompensated heart failure: limited role for nesiritide.Quality of life assessment in heart failure interventions: a 10-year (1996-2005) review.Nesiritide: the clinical experience.The Importance of Amino-terminal pro-Brain Natriuretic Peptide Testing in Clinical Cardiology.Vasodilators in the treatment of acute heart failure: what we know, what we don't.Role of natriuretic peptides in cardiovascular surgery.The role of nesiritide in heart failure.Efficacy and safety of nesiritide in patients with acute decompensated heart failure.Therapeutic adjustments in stage D heart failure: challenges and strategies.Natriuretic peptides for the treatment of acute heart failure: a focus on nesiritide in recent clinical trials.Management of acute decompensated heart failure: treatment, controversy, and future directions.Current and future uses of nesiritide.The tumultuous journey of nesiritide: past, present, and future.Clinical implications of defective B-type natriuretic peptide.The potential of the inodilator levosimendan in maintaining quality of life in advanced heart failure.Effect of nesiritide infusion duration on renal function in acutely decompensated heart failure patients.Intact acute cardiorenal and humoral responsiveness following chronic subcutaneous administration of the cardiac peptide BNP in experimental heart failure.Acute study of clinical effectiveness of nesiritide in decompensated heart failure: nesiritide redux.
P2860
Q28078389-E8F01850-0D8A-4529-9CFF-8722B314B7D1Q33878162-9F8695CA-E1DA-4A64-BDC4-62DFA42E7BE1Q36050051-73196D60-4CB6-43B3-9392-7301A0E28E7BQ36249926-F7425D03-9790-4ECE-8FDD-1AA2477BD42AQ36382621-1829A469-3F4A-4F24-82AB-2DC796B6A83FQ36390922-0FB722F9-17D6-42A2-8D8A-5D811685ECCEQ36564032-D598A1BF-522B-41E0-A173-23898E59B1C5Q36603228-C4C5F68F-9D00-43F9-A8D9-4DF6F2895DCBQ36802561-E05DBB7C-FF7A-4811-A67E-94D3102AB32AQ36802563-51A87E0E-CE04-4B96-BD28-9FDB52DB8D61Q36966553-9746BDAF-B8C6-45E1-AB21-44406E559A70Q37217350-AC3895E8-894B-4922-919F-8A92E942874FQ37277937-128BED98-71CA-49F1-80E4-E96F4B5BF2F1Q37355110-50740B2F-2B00-465A-8525-CE6146B7255AQ37472052-94FF8DFE-FF35-43B4-947B-EDC09A32E994Q37523958-79245788-18B6-43ED-848B-E0DBBF046B48Q37688147-05A61DF3-4A95-4571-94ED-AB0C9DB20789Q38267665-7BD96155-8084-4069-BD79-5C99CD58F6C2Q38509576-A5410C57-A181-4B81-979B-9DEA45DFCCDEQ40304351-76FAAF5C-A832-4864-BC3C-2D9E588B3C49Q40442907-ED5E1186-1490-4C77-A603-EFF6679BB885Q43123466-8B11052A-610B-4465-89EF-99282C720FE7Q43219078-9BD4D8E2-BDB7-47AF-B2BD-5343FAEFBAC1Q47158526-C931FB13-834F-4F12-A7C6-85E7373B8880Q48227077-172AC016-421A-4DE6-A42A-6CF1A8A1722EQ48662099-36ABE9B9-AE38-4D77-9B10-A03EF03CBC77Q49141047-64040AAD-5E2E-42DD-99F6-3BB41D02B691
P2860
Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial).
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Safety and feasibility of usin ...... ing (from the FUSION I trial).
@en
Safety and feasibility of usin ...... ilure in an outpatient setting
@nl
type
label
Safety and feasibility of usin ...... ing (from the FUSION I trial).
@en
Safety and feasibility of usin ...... ilure in an outpatient setting
@nl
prefLabel
Safety and feasibility of usin ...... ing (from the FUSION I trial).
@en
Safety and feasibility of usin ...... ilure in an outpatient setting
@nl
P2093
P1476
Safety and feasibility of usin ...... ing (from the FUSION I trial).
@en
P2093
Barry Bertolet
Darlene P Horton
Kenneth Burnham
Kirk Walker
Krishnaswami Vijayaraghavan
Marc A Silver
Mitchell T Saltzberg
Robert L Berkowitz
Ron M Oren
P304
P356
10.1016/J.AMJCARD.2004.05.022
P407
P50
P577
2004-09-01T00:00:00Z